Cargando…
Nasal-type NK/T cell lymphoma: clinical features and treatment outcome
Nasal-type NK/T cell lymphoma is an increasingly recognised disease entity of aggressive clinical behaviour. The objective of this study was to investigate clinical features and treatment outcomes in patients with nasal-type NK/T cell lymphoma. From January 1991 to December 2003, 26 patients diagnos...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361983/ https://www.ncbi.nlm.nih.gov/pubmed/15798768 http://dx.doi.org/10.1038/sj.bjc.6602502 |
_version_ | 1782153350154813440 |
---|---|
author | Lee, J Kim, W S Park, Y H Park, S H Park, K W Kang, J H Lee, S S Lee, S I Lee, S-H Kim, K Jung, C W Ahn, Y C Ko, Y H Park, K |
author_facet | Lee, J Kim, W S Park, Y H Park, S H Park, K W Kang, J H Lee, S S Lee, S I Lee, S-H Kim, K Jung, C W Ahn, Y C Ko, Y H Park, K |
author_sort | Lee, J |
collection | PubMed |
description | Nasal-type NK/T cell lymphoma is an increasingly recognised disease entity of aggressive clinical behaviour. The objective of this study was to investigate clinical features and treatment outcomes in patients with nasal-type NK/T cell lymphoma. From January 1991 to December 2003, 26 patients diagnosed as nasal-type NK/T cell lymphoma were included in the analysis. One half of patients presented with poor performance status (ECOG ⩾2); 46% of patients were categorised as high intermediate or high-risk group according to IPI; and 46% of patients were diagnosed at advanced stage. The median survival for 26 patients with nasal-type NK/T cell lymphoma was 7.4 months (95% CI, 0.1, 16.9). The treatment outcome of primary anthracycline-based chemotherapy was poor: 60% CR rate in localised disease and 0% CR rate in advanced disease. After a median follow-up of 24.4 months (range 3.1–99.0) in patients with localised disease who had achieved a CR (range 29.6–165.7), three patients (50.0%) developed disease recurrence at 6.1, 21.8, and 52.1 months, respectively, and all patients presented with locoregional failure. The predictive factors for poor survival were of age greater than 60, advanced stage and poor performance in multivariate analysis. In conclusion, Nasal-type NK/T cell lymphomas showed a poor response to the conventional anthracycline-based chemotherapy, and thus an investigation for an innovative therapy is urgently needed to improve survival in these patients. |
format | Text |
id | pubmed-2361983 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2005 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23619832009-09-10 Nasal-type NK/T cell lymphoma: clinical features and treatment outcome Lee, J Kim, W S Park, Y H Park, S H Park, K W Kang, J H Lee, S S Lee, S I Lee, S-H Kim, K Jung, C W Ahn, Y C Ko, Y H Park, K Br J Cancer Clinical Study Nasal-type NK/T cell lymphoma is an increasingly recognised disease entity of aggressive clinical behaviour. The objective of this study was to investigate clinical features and treatment outcomes in patients with nasal-type NK/T cell lymphoma. From January 1991 to December 2003, 26 patients diagnosed as nasal-type NK/T cell lymphoma were included in the analysis. One half of patients presented with poor performance status (ECOG ⩾2); 46% of patients were categorised as high intermediate or high-risk group according to IPI; and 46% of patients were diagnosed at advanced stage. The median survival for 26 patients with nasal-type NK/T cell lymphoma was 7.4 months (95% CI, 0.1, 16.9). The treatment outcome of primary anthracycline-based chemotherapy was poor: 60% CR rate in localised disease and 0% CR rate in advanced disease. After a median follow-up of 24.4 months (range 3.1–99.0) in patients with localised disease who had achieved a CR (range 29.6–165.7), three patients (50.0%) developed disease recurrence at 6.1, 21.8, and 52.1 months, respectively, and all patients presented with locoregional failure. The predictive factors for poor survival were of age greater than 60, advanced stage and poor performance in multivariate analysis. In conclusion, Nasal-type NK/T cell lymphomas showed a poor response to the conventional anthracycline-based chemotherapy, and thus an investigation for an innovative therapy is urgently needed to improve survival in these patients. Nature Publishing Group 2005-04-11 2005-03-29 /pmc/articles/PMC2361983/ /pubmed/15798768 http://dx.doi.org/10.1038/sj.bjc.6602502 Text en Copyright © 2005 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Clinical Study Lee, J Kim, W S Park, Y H Park, S H Park, K W Kang, J H Lee, S S Lee, S I Lee, S-H Kim, K Jung, C W Ahn, Y C Ko, Y H Park, K Nasal-type NK/T cell lymphoma: clinical features and treatment outcome |
title | Nasal-type NK/T cell lymphoma: clinical features and treatment outcome |
title_full | Nasal-type NK/T cell lymphoma: clinical features and treatment outcome |
title_fullStr | Nasal-type NK/T cell lymphoma: clinical features and treatment outcome |
title_full_unstemmed | Nasal-type NK/T cell lymphoma: clinical features and treatment outcome |
title_short | Nasal-type NK/T cell lymphoma: clinical features and treatment outcome |
title_sort | nasal-type nk/t cell lymphoma: clinical features and treatment outcome |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361983/ https://www.ncbi.nlm.nih.gov/pubmed/15798768 http://dx.doi.org/10.1038/sj.bjc.6602502 |
work_keys_str_mv | AT leej nasaltypenktcelllymphomaclinicalfeaturesandtreatmentoutcome AT kimws nasaltypenktcelllymphomaclinicalfeaturesandtreatmentoutcome AT parkyh nasaltypenktcelllymphomaclinicalfeaturesandtreatmentoutcome AT parksh nasaltypenktcelllymphomaclinicalfeaturesandtreatmentoutcome AT parkkw nasaltypenktcelllymphomaclinicalfeaturesandtreatmentoutcome AT kangjh nasaltypenktcelllymphomaclinicalfeaturesandtreatmentoutcome AT leess nasaltypenktcelllymphomaclinicalfeaturesandtreatmentoutcome AT leesi nasaltypenktcelllymphomaclinicalfeaturesandtreatmentoutcome AT leesh nasaltypenktcelllymphomaclinicalfeaturesandtreatmentoutcome AT kimk nasaltypenktcelllymphomaclinicalfeaturesandtreatmentoutcome AT jungcw nasaltypenktcelllymphomaclinicalfeaturesandtreatmentoutcome AT ahnyc nasaltypenktcelllymphomaclinicalfeaturesandtreatmentoutcome AT koyh nasaltypenktcelllymphomaclinicalfeaturesandtreatmentoutcome AT parkk nasaltypenktcelllymphomaclinicalfeaturesandtreatmentoutcome |